Changes in current Evaluation of new Drugs needs Survey of pharma-economic Data: Treatment Satisfaction of Fingolimod (Gilenya) in Comparison to First-Line-Therapeutics in Multiple Sclerosis Patients (PANGAEA and PEARL)

被引：0

|

作者：

Ziemssen, Tjalf ^{[1
]}

van Lokven, Tom ^{[1
]}

Ortler, Sonja ^{[1
]}

Meergans, Matthias ^{[1
]}

机构：

[1] Klinikum Carl Gustav Carus, Klin & Poliklin Neurol, D-01307 Dresden, Germany

来源：

AKTUELLE NEUROLOGIE | 2012年 / 39卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

收藏

页码：385 / 385

页数：1

相关论文

共 3 条

[1] Interim Results of the PANGAEA and PEARL Studies, Comparing Treatment Satisfaction and Pharmaco-Economic Data of Fingolimod (Gilenya®) and First-Line Therapies in Multiple Sclerosis Patients in Germany
Ziemssen, Tjalf
Vollmar, Patrick
Meergans, Matthias
Tracik, Ferenc Mark
Lorente, Maria Diaz
Neidhardt, Katja
van Lokven, Tom
NEUROLOGY, 2013, 80
[2] First interim results on treatment satisfaction and pharmaco-economic data comparing Fingolimod and first-line therapies in multiple sclerosis patients in Germany (PANGAEA and PEARL)
Ortler, Sonja
Ziemssen, Tjalf
Antonius, van Lokven
Meergans, Matthias
JOURNAL OF NEUROIMMUNOLOGY, 2012, 253 (1-2) : 31 - 32
[3] First interim results on treatment satisfaction and pharmacoeconomic data comparing fingolimod and first-line therapies in multiple sclerosis patients in Germany (PANGAEA and PEARL)
Ortler, S.
Ziemssen, T.
Meergans, M.
Tracik, F.
van Lokven, A.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 113 - 113